Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

  • Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300.
R Suzuki  1 ,  T Hideshima  1 ,  N Mimura  1 ,  J Minami  1 ,  H Ohguchi  1 ,  S Kikuchi  1 ,  Y Yoshida  1 ,  G Gorgun  1 ,  D Cirstea  1 ,  F Cottini  1 ,  J Jakubikova  1 ,  Y-T Tai  1 ,  D Chauhan  1 ,  P G Richardson  1 ,  N C Munshi  2 ,  T Utsugi  3 ,  K C Anderson  1
Affiliations
  • 1. Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 2. VA Boston Healthcare System, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 3. Tsukuba Research Center, TAIHO PHARMACEUTICAL CO. LTD., Tsukuba, Japan.
PMID: 25306900 DOI: 10.1038/leu.2014.300
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15785
    Pimitespib
    99.87%, HSP90α/HSP90β Inhibitor
    target: HSP
    Research Areas: Cancer